Literature DB >> 18463515

Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Eriko Akaza1, Ryusaburo Mori, Mitsuko Yuzawa.   

Abstract

PURPOSE: This study evaluated the results of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) 24 months or more after treatment.
METHODS: The study involved 47 eyes of 47 patients with PCV followed for 24 months or more after the first PDT. Fundus appearance, indocyanine green angiographic findings, and visual acuity (VA) were compared before PDT, and then at 3 months, 12 months, and the final visit after the first PDT.
RESULTS: At the final visit, VA was preserved or improved in 37 (79%) of the 47 eyes. Recurrence of polypoidal lesions was noted in 30 eyes (64%). An abnormal branching vascular network persisted in all subjects. In 26 of the 30 eyes exhibited recurrence of polypoidal lesions, which appeared in the periphery of the expanded abnormal branching vascular network.
CONCLUSION: Patients with PCV need to be followed for long periods of time after PDT because of the high incidence of polypoidal lesion recurrence. However, since polypoidal lesions often recur outside the fovea, and thus have little effect on VA, PDT can be expected to exert long-term efficacy in treating PCV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18463515     DOI: 10.1097/IAE.0b013e31816577cb

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  42 in total

1.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

2.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

3.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

4.  Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Authors:  Ryusaburo Mori; Mitsuko Yuzawa; Zeon Lee; Miho Haruyama; Eriko Akaza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-30       Impact factor: 3.117

5.  Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy.

Authors:  A Oishi; M Mandai; M Kimakura; A Nishida; Y Kurimoto
Journal:  Eye (Lond)       Date:  2011-05-06       Impact factor: 3.775

6.  Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

7.  Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review.

Authors:  Meng Zhao; Hai-Ying Zhou; Jun Xu; Feng Zhang; Wen-Bin Wei; Ning-Pu Liu
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

8.  Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Yukinori Sugano; Tomohiro Iida; Ichiro Maruko; Akira Ojima; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2013-02-14       Impact factor: 2.447

9.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-05       Impact factor: 3.117

10.  Clinical features, management and visual outcome of polypoidal choroidal vasculopathy in Indian patients.

Authors:  Giridhar Anantharaman; Gudapati Ramkumar; Mahesh Gopalakrishnan; Alpesh Rajput
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.